ETH 47
Alternative Names: ETH-47Latest Information Update: 15 Jun 2026
At a glance
- Originator ethris
- Developer Ethris
- Class Antivirals; RNA
- Mechanism of Action Interferon lambda replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Viral infections
- No development reported COVID 2019 infections; Influenza A virus infections
Most Recent Events
- 01 Oct 2025 Pharmacodynamics data from a preclinical study in Influenza A and COVID-19 virus infections presented at the 35th Annual Congress of the European Respiratory Society (ERS-2025)
- 01 Oct 2025 Pharmacodynamics and adverse events data from a phase I trial in Viral infections presented at the 35th Annual Congress of the European Respiratory Society (ERS-2025)
- 05 Aug 2025 Ethris plans a phase IIb trial for Viral infections